Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy

Pediatric Drugs

Volumn 17, Issue 4, 2015, Pages 257-271

  Rivera Valentin, Rocio K ^a   Zhu, Limin ^a   Hughes, Dennis P M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CEDIRANIB; DASATINIB; DENOSUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN; METALLOPROTEINASE; MIFAMURTIDE; NOTCH RECEPTOR; PAZOPANIB; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN MDM2; PROTEIN TYROSINE KINASE; RADIOISOTOPE; RAS PROTEIN; SARGRAMOSTIM; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; SORAFENIB; STEROID RECEPTOR COACTIVATOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BONE METABOLISM; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL MIGRATION; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EWING SARCOMA; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; INTRACELLULAR SIGNALING; OSTEOSARCOMA; PEDIATRICS; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; BONE NEOPLASMS; CHILD; SARCOMA, EWING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; HUMANS; OSTEOSARCOMA; PEDIATRICS; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 84938416643     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-015-0134-4     Document Type: Article

References (183)

1. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 2004;42(5):410–5 (Epub 2004/03/30).
2. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.
3. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11(7):670–8.
4. Sybil Biermann J, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, et al. Bone cancer: clinical practice guidelines in oncology. JNCCN. 2013;11(6):688–723.
5. Whelan J, Seddon B, Perisoglu M. Management of osteosarcoma. Curr Treat Options Oncol. 2006;7(6):444–55.
6. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423–36 (Epub 2006/07/25).
7. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI, et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol. 2007;40(6):1069–76 (Epub 2007/12/01).
8. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs. 2010;28(6):766–82 (Epub 2009/09/05).
9. Hughes DP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res. 2009;152:479–96 (Epub 2010/03/10).
10. Ando K, Mori K, Verrecchia F, Marc B, Redini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma. 2012;2012:523432 (Epub 2012/03/27).
11. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742–57 (Epub 2007/05/22).
12. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904 (Epub 2006/08/08).
13. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11(7):2561–7 (Epub 2005/04/09).
14. Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, et al. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol. 2009;221(1):204–12 (Epub 2009/06/06).
15. Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, Vandenbos F, et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer. 2009;125(11):2586–94 (Epub 2009/06/23).
16. Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, et al. Bone cancer. J Natl Compr Canc Netw. 2013;11(6):688–723.
17. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.
18. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25(3):201–11 (Epub 2007/12/12).
19. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol. 2008;26(4):633–8.
20. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer. 2001;8(3):161–73 (Epub 2001/09/22).
21. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99 (Epub 2012/09/18).
22. Jully B, Rajkumar T. Potential molecular targets for Ewing’s sarcoma therapy. Indian J Med Paediatr Oncol. 2012;33(4):195–202 (Epub 2013/04/13).
23. Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol. 2013;4:30 (Epub 2013/03/26).
24. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28 (Epub 2008/11/26).
25. van Valen F, Winkelmann W, Jurgens H. Type I and type II insulin-like growth factor receptors and their function in human Ewing’s sarcoma cells. J Cancer Res Clin Oncol. 1992;118(4):269–75 (Epub 1992/01/01).
26. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1996;56(20):4570–4 (Epub 1996/10/15).
27. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, et al. Cell surface receptor expression patterns in osteosarcoma. Cancer. 2012;118(3):740–9 (Epub 2011/07/14).
28. Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 2012;105(3):235–43 (Epub 2011/08/26).
29. Martin Liberal J, Lagares-Tena L, Sainz-Jaspeado M, Mateo-Lozano S, Garcia Del Muro X, Tirado OM. Targeted therapies in sarcomas: challenging the challenge. Sarcoma. 2012;2012:626094 (Epub 2012/06/16).
30. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014;120(16):2448–56.
31. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29(34):4534–40 (Epub 2011/10/26).
32. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013;49(15):3219–28 (Epub 2013/07/10).
33. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(3):256–62 (Epub 2011/12/21).
34. von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, et al. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014;32(3):518–25 (Epub 2014/01/25).
35. Soria JC, Massard C, Lazar V, Ozoux ML, Mery-Mignard D, Deslandes A, et al. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer. 2013;49(8):1799–807 (Epub 2013/03/15).
36. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012;30(15):1849–56 (Epub 2012/04/18).
37. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6304–12 (Epub 2011/08/04).
38. Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, et al. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther. 2014;13(2):399–409 (Epub 2013/12/04).
39. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 2011;71(3):1029–40 (Epub 2011/01/20).
40. Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, et al. Phase I dose escalation study of MEDI-573, a bispecific, anti-ligand monoclonal antibody against IGF-I and IGF-II, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(18):4747–57.
41. Feng Y, Dimitrov DS. Antibody-based therapeutics against components of the IGF system. Oncoimmunology. 2012;1(8):1390–1 (Epub 2012/12/18).
42. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28(34):3009–21 (Epub 2009/07/08).
43. Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 2001;60(4):361–6.
44. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 2001;92(3):677–83.
45. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 2001;14(12):1277–83.
46. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res. 2002;8(3):788–93.
47. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 2002;94(5):1397–404.
48. Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, et al. HER-2 expression is not prognostic in osteosarcoma; a Children’s Oncology Group prospective biology study. Pediatr Blood Cancer. 2014;61(9):1558–64 (Epub 2014/04/23).
49. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77(1):71–8.
50. Zhou H, Randall R, Brothman A, Maxwell T, Coffin C, Goldsby R. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 2003;25(1):27–32.
51. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17(9):2781–8.
52. Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch D. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest. 2004;84(1):113–21.
53. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100(9):1936–42.
54. McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 2010;28(26):4022–8.
55. Li YG, Geng X. A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care. 2010;19(3):313–6 (Epub 2009/08/28).
56. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomark Prev. 2004;13(4):667–72.
57. Xie R, Chung J-Y, Ylaya K, Williams RL, Guerrero N, Nakatsuka N, et al. Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. J Histochem Cytochem. 2011;59(4):356–65.
58. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol. 2012;30(20):2545–51 (Epub 2012/06/06).
59. Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009;14(11):1061–9 (Epub 2009/11/06).
60. Hua Y, Gorshkov K, Yang Y, Wang W, Zhang N, Hughes DP. Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastoma. Cancer. 2012;118(20):5140–54 (Epub 2012/03/15).
61. Hua Y, Yang Y, Hughes D. Abstract 197: multi-cellular tumor spheroids in vitro model reveals a critical role of ERBB4 in survival of osteosarcoma. Cancer Res. 2011;71(8 Suppl):197.
62. Kang H-G, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007;67(7):3094–105.
63. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004;64(6):2047–53 (Epub 2004/03/18).
64. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013;5(7):1019–34 (Epub 2013/05/18).
65. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15(4):197–204 (Epub 2004/06/23).
66. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, et al. Inhibiting platelet-derived growth factor beta reduces Ewing’s sarcoma growth and metastasis in a novel orthotopic human xenograft model. Vivo. 2009;23(6):903–9 (Epub 2009/12/22).
67. Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, et al. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing’s sarcoma cells. Oncogene. 2003;22(15):2334–42 (Epub 2003/04/18).
68. Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A. Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol. 2000;13(6):632–7 (Epub 2000/06/30).
69. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008;112(10):2119–29.
70. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50(2):254–8 (Epub 2007/01/31).
71. Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010;30(2):547–52 (Epub 2010/03/25).
72. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004;10(2):175–81.
73. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6 (Epub 2004/01/06).
74. Ren L, Khanna C. Role of ezrin in osteosarcoma metastasis. Adv Exp Med Biol. 2014;804:181–201.
75. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 2006;23(3–4):227–36.
76. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012;31(3):269–81.
77. Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res. 2009;152:517–28.
78. Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833–9.
79. Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014;344(2):291–8.
80. Martin-Liberal J, Gil-Martin M, Sainz-Jaspeado M, Gonzalo N, Rigo R, Colom H, et al. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. Br J Cancer. 2014;111(5):858–65.
81. Mita MM, Gong J, Chawla SP. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas. Expert Rev Clin Pharmacol. 2013;6(5):465–82.
82. Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, et al. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. Clin Cancer Res. 2013;19(13):3649–58.
83. Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer. 2008;50(5):976–82.
84. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31(19):2485–92.
85. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res. 2009;15(10):3416–22.
86. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 2007;67(6):2800–8.
87. Timeus F, Crescenzio N, Fandi A, Doria A, Foglia L, Cordero di Montezemolo L. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep. 2008;19(2):353–9.
88. Ott U, Odermatt E, Engel J, Furthmayr H, Timpl R. Protease resistance and conformation of laminin. Eur J Biochem. 1982;123(1):63–72.
89. Takahashi S, Miyazaki M, Okamoto I, Ito Y, Ueda K, Seriu T, et al. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. Cancer Sci. 2011;102(11):2058–64.
90. Paridaen JT, Huttner WB. Neurogenesis during development of the vertebrate central nervous system. EMBO Rep. 2014;15(4):351–64.
91. McManus MM, Weiss KR, Hughes DPM. Understanding the role of notch in osteosarcoma. In: Kleinerman ES, editor. Current advances in osteosarcoma. New York: Springer Science and Business Media; 2014.
92. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood. 2011;117(2):719–26.
93. Engin F, Bertin T, Ma O, Jiang MM, Wang L, Sutton RE, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009;18(8):1464–70.
94. Hughes DPM. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. In: Jaffe N, Bruland OS, Bielack S, editors. Pediatric and adolescent osteosarcoma. 152nd ed. New York: Springer; 2009. p. 479–96.
95. Mu X, Isaac C, Greco N, Huard J, Weiss K. Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells. Front Oncol. 2013;3.
96. McManus MM, Weiss KR, Hughes DP. Understanding the role of notch in osteosarcoma. Adv Exp Med Biol. 2014;804:67–92.
97. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30(19):2348–53.
98. Hughes DPM, Kummar S, Lazar AJ. New, tolerable {gamma}-secretase inhibitor takes desmoid down a notch. Clin Cancer Res. 2015;21(1):7–9.
99. Lo WW, Pinnaduwage D, Gokgoz N, Wunder JS, Andrulis IL. Aberrant hedgehog signaling and clinical outcome in osteosarcoma. Sarcoma. 2014;2014:261804.
100. Lo WW, Wunder JS, Dickson BC, Campbell V, McGovern K, Alman BA, et al. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. Cancer. 2014;120(4):537–47.
101. Kelleher FC, Cain JE, Healy JM, Watkins DN, Thomas DM. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 2012;136(2):153–68.
102. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 2009;4(10):e7608.
103. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Investig. 2011;121(1):148–60.
104. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(5):1044–51.
105. Kimura H, Ng JMY, Curran T. Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008;13(3):249–60.
106. Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol. 2006;24(22):3678–85.
107. Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013;60(11):1868–74.
108. Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP, et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2012;2(1):8.
109. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, et al. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res. 2015;32(3):779–92.
110. Geryk-Hall M, Yang Y, Hughes DP. Driven to death: inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol Cancer Ther. 2010;9(5):1111–9.
111. Tsubaki M, Satou T, Itoh T, Imano M, Ogaki M, Yanae M, et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol Appl Pharmacol. 2012;259(3):402–10.
112. Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, et al. Blockade of the Ras/MEK/ERK and Ras/PI3 K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-beta as angiogenic factors in mouse osteosarcoma. Cytokine. 2011;54(1):100–7.
113. Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, et al. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 2013;8(9):893–8.
114. Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer. 2011;117(8):1764–74.
115. Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, et al. A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. ASCO Meeting Abstracts. 2009;27(15S):10524.
116. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res. 2011;17(3):494–504.
117. Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells. Eur J Cancer. 2011;47(9):1432–41.
118. Wang B, Fang L, Zhao H, Xiang T, Wang D. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim Biophys Sin. 2012;44(8):685–91.
119. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, et al. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2013;60(4):633–41.
120. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591–6.
121. Fang H, DeClerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013;73(16):4965–77.
122. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res. 2014;12(3):297–312.
123. Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res. 2012;18(3):645–53.
124. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Investig. 1991;88(6):2095–105 (Epub 1991/12/01).
125. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer. 2000;88(12 Suppl):3080–8 (Epub 2000/07/18).
126. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer. 2005;104(8):1713–20 (Epub 2005/08/27).
127. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005;104(11):2522–9 (Epub 2005/11/05).
128. Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, et al. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration. BMC Cancer. 2014;14:169 (Epub 2014/03/13).
129. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing’s sarcoma patients. Cancer Res. 2010;70(19):7610–9 (Epub 2010/09/16).
130. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing’s sarcoma cell growth in vitro. Anticancer Drugs. 2003;14(9):767–71 (Epub 2003/10/11).
131. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther. 2007;6(12 Pt 1):3263–70 (Epub 2007/12/20).
132. Goldenberg DM, Schlom J. The coming of age of cancer radioimmunoconjugates. Immunol Today. 1993;14(1):5–7 (Epub 1993/01/01).
133. Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011;117(8):1736–44 (Epub 2011/04/08).
134. Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Eur J Cancer. 2013;49(10):2384–91 (Epub 2013/05/15).
135. Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother. 2006;7(11):1475–86 (Epub 2006/07/25).
136. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23 (Epub 2013/07/19).
137. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005;11(19 Pt 1):6895–900 (Epub 2005/10/06).
138. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–46.
139. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12(1):17–25.
140. Lee JA, Jung JS, Kim DH, Lim JS, Kim MS, Kong C-B, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer. 2011;56(5):738–43.
141. Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol. 2007;211(5):555–62 (Epub 2007/02/27).
142. Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci. 2012;125(Pt 4):943–55 (Epub 2012/03/17).
143. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–31 (Epub 2006/02/24).
144. Body J-J, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221–8.
145. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.
146. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–32.
147. Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.
148. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.
149. Langley R, Fidler I. The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128(11):2527–35.
150. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
151. Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5(2):591–616.
152. Anderson PM, Tomaras M, McConnell K. Mifamurtide in osteosarcoma–a practical review. Drugs Today (Barcelona, Spain: 1998). 2010;46(5):327–37 (Epub 2010/06/03).
153. O’Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther. 2009;9(4):511–23 (Epub 2009/04/21).
154. Pedrazzoli P, Secondino S, Perfetti V, Comoli P, Montagna D. Immunotherapeutic intervention against sarcomas. J Cancer. 2011;2:350–6.
155. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res. 2006;16(2):126–33.
156. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999;5(9):2316–23.
157. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci. 1993;90(8):3539–43.
158. Kumar R, Yoneda J, Fidler IJ, Dong Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol. 1999;65(1):102–8.
159. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children’s Oncology Group. Clin Cancer Res. 2010;16(15):4024–30.
160. Okuno S, Petersen I, Shives T, Mahoney M, Haddock M, Sim F, et al. Chemotherapy, irradiation, and surgery for function-preserving curative therapy of primary extremity soft tissue sarcomas: initial treatment with I-MAP and inhalation GM-CSF during preoperative irradiation and postoperatively. Am J Clin Oncol. 2014. (Epub 30 Jan).
161. Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer. 1977;19(4):468–73.
162. Bielack SS, Smeland S, Whelan J, Marina N, Hook J, Jovic G, et al. MAP plus maintenance pegylated interferon {alpha}-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization. ASCO Meeting Abstracts. 2013;31(18 Suppl):LBA10504.
163. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96 (Epub 1995/03/01).
164. Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014;61(8):1362–8.
165. Guma SR, Lee DA, Yu L, Gordon N, Hughes D, Stewart J, et al. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014;61(4):618–26.
166. Zhu L, McManus MM, Hughes DP. Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Front Oncol. 2013;3:230 (Epub 2013/09/26).
167. Mortus JR, Zhang Y, Hughes DPM. developmental pathways hijacked by osteosarcoma. In: Kleinerman ES, editor. Current advances in osteosarcoma. New York: Springer Science and Business Media; 2014.
168. Xin ZF, Kim YK, Jung ST. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res. 2009;28:105 (Epub 2009/07/25).
169. Ferrari C, Benassi S, Ponticelli F, Gamberi G, Ragazzini P, Pazzaglia L, et al. Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand. 2004;75(4):487–91.
170. Liu B, Li G, Wang X, Liu Y. A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of MT1-MMP via the Wnt signaling pathway. Oncol Lett. 2014;7(4):1033–8.
171. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing’s sarcoma family. Clin Cancer Res. 2005;11(6):2364–78 (Epub 2005/03/25).
172. Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53(6):1035–9 (Epub 2009/07/22).
173. Zhang F, Yang Q, Meng F, Shi H, Li H, Liang Y, et al. Astrocyte elevated gene-1 interacts with beta-catenin and increases migration and invasion of colorectal carcinoma. Mol Carcinog. 2013;52(8):603–10 (Epub 2012/03/21).
174. Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C, et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing’s sarcoma. Eur J Cancer. 2006;42(12):1904–11 (Epub 2006/07/11).
175. DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010;116(3):749–57 (Epub 2009/12/24).
176. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008;26(3):399–405 (Epub 2008/01/19).
177. Skubitz KM, Haddad PA. Combination of pegylated-liposomal doxorubicin (PLD) and bevacizumab (B) (PLD-B) in sarcoma (SAR). ASCO Meeting Abstracts. 2007;25(18 Suppl):20506.
178. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014;20(16):4200–9 (Epub 2014/05/08).
179. Anderson P, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. In: Kleinerman MDES, editor. Current advances in osteosarcoma. Springer Cham Heidelberg New York Dordrecht London: Springer International Publishing; 2014. p. 291–304.
180. Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, et al. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res. 2014;20(10):2783–92 (Epub 2014/03/19).
181. Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107 (Epub 2014/12/17).
182. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813 (Epub 2014/11/07).
183. Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32(14):1445–52 (Epub 2014/04/09).